| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polymorphism, Single Nucleotide | 224 | 2021 | 1050 | 9.140 |
Why?
|
| Genetic Predisposition to Disease | 179 | 2021 | 821 | 9.090 |
Why?
|
| African Americans | 153 | 2021 | 1335 | 7.580 |
Why?
|
| Lupus Erythematosus, Systemic | 64 | 2020 | 149 | 6.100 |
Why?
|
| Genome-Wide Association Study | 102 | 2021 | 543 | 5.430 |
Why?
|
| Diabetes Mellitus, Type 2 | 119 | 2019 | 1437 | 5.300 |
Why?
|
| Cerebral Hemorrhage | 32 | 2021 | 72 | 4.350 |
Why?
|
| European Continental Ancestry Group | 96 | 2021 | 1076 | 4.010 |
Why?
|
| Hispanic Americans | 70 | 2021 | 772 | 3.590 |
Why?
|
| Kidney Failure, Chronic | 51 | 2019 | 534 | 3.490 |
Why?
|
| Genetic Variation | 36 | 2019 | 248 | 2.760 |
Why?
|
| Apolipoproteins | 25 | 2016 | 194 | 2.760 |
Why?
|
| Genotype | 122 | 2021 | 702 | 2.740 |
Why?
|
| Lipoproteins, HDL | 26 | 2018 | 250 | 2.720 |
Why?
|
| Humans | 418 | 2021 | 32274 | 2.700 |
Why?
|
| Diabetic Nephropathies | 35 | 2019 | 223 | 2.630 |
Why?
|
| Insulin Resistance | 39 | 2020 | 458 | 2.520 |
Why?
|
| Middle Aged | 245 | 2021 | 11848 | 2.510 |
Why?
|
| Female | 315 | 2021 | 19942 | 2.490 |
Why?
|
| Male | 311 | 2021 | 19437 | 2.490 |
Why?
|
| Genome, Human | 22 | 2020 | 130 | 2.070 |
Why?
|
| Case-Control Studies | 79 | 2019 | 854 | 2.030 |
Why?
|
| Adult | 166 | 2020 | 9256 | 1.820 |
Why?
|
| Aged | 163 | 2021 | 10260 | 1.800 |
Why?
|
| African Continental Ancestry Group | 26 | 2021 | 338 | 1.780 |
Why?
|
| Lupus Nephritis | 9 | 2018 | 29 | 1.740 |
Why?
|
| Chromosome Mapping | 33 | 2020 | 188 | 1.700 |
Why?
|
| Alleles | 46 | 2020 | 250 | 1.680 |
Why?
|
| Quantitative Trait Loci | 26 | 2021 | 140 | 1.660 |
Why?
|
| Haplotypes | 64 | 2020 | 213 | 1.660 |
Why?
|
| Adiposity | 18 | 2018 | 190 | 1.550 |
Why?
|
| Linkage Disequilibrium | 45 | 2019 | 181 | 1.520 |
Why?
|
| Gene Frequency | 50 | 2019 | 211 | 1.490 |
Why?
|
| Genetic Loci | 26 | 2019 | 143 | 1.470 |
Why?
|
| Phenotype | 50 | 2021 | 621 | 1.430 |
Why?
|
| Molecular Motor Proteins | 15 | 2015 | 59 | 1.390 |
Why?
|
| Obesity | 23 | 2020 | 1111 | 1.380 |
Why?
|
| Myosin Heavy Chains | 15 | 2015 | 84 | 1.380 |
Why?
|
| Membrane Proteins | 15 | 2019 | 243 | 1.310 |
Why?
|
| Adipose Tissue | 16 | 2020 | 320 | 1.290 |
Why?
|
| Atherosclerosis | 24 | 2018 | 820 | 1.280 |
Why?
|
| Kidney Diseases | 16 | 2019 | 243 | 1.270 |
Why?
|
| Cardiovascular Diseases | 23 | 2019 | 1158 | 1.240 |
Why?
|
| Genomics | 5 | 2020 | 89 | 1.230 |
Why?
|
| Genetic Association Studies | 28 | 2019 | 146 | 1.140 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2019 | 293 | 1.130 |
Why?
|
| Polymorphism, Genetic | 17 | 2018 | 179 | 1.110 |
Why?
|
| Risk Factors | 77 | 2020 | 3934 | 1.100 |
Why?
|
| Cohort Studies | 52 | 2020 | 1840 | 1.040 |
Why?
|
| Models, Genetic | 17 | 2018 | 93 | 1.030 |
Why?
|
| DNA | 11 | 2020 | 223 | 0.980 |
Why?
|
| Albuminuria | 17 | 2019 | 172 | 0.950 |
Why?
|
| Continental Population Groups | 12 | 2019 | 228 | 0.940 |
Why?
|
| Calcinosis | 16 | 2016 | 143 | 0.920 |
Why?
|
| Bone Density | 12 | 2018 | 169 | 0.910 |
Why?
|
| Adiponectin | 12 | 2017 | 94 | 0.880 |
Why?
|
| Aged, 80 and over | 47 | 2021 | 3898 | 0.830 |
Why?
|
| Mexican Americans | 9 | 2019 | 52 | 0.810 |
Why?
|
| Research Design | 3 | 2021 | 314 | 0.800 |
Why?
|
| Blood Pressure | 14 | 2020 | 861 | 0.780 |
Why?
|
| HLA Antigens | 6 | 2020 | 40 | 0.770 |
Why?
|
| Disease Progression | 12 | 2019 | 591 | 0.760 |
Why?
|
| Hypertension | 18 | 2021 | 979 | 0.760 |
Why?
|
| Stroke | 11 | 2020 | 691 | 0.740 |
Why?
|
| Computer Simulation | 4 | 2021 | 251 | 0.730 |
Why?
|
| Adolescent | 37 | 2019 | 3517 | 0.720 |
Why?
|
| Coronary Artery Disease | 15 | 2015 | 427 | 0.720 |
Why?
|
| Glucose | 13 | 2020 | 160 | 0.720 |
Why?
|
| Ethnic Groups | 14 | 2020 | 450 | 0.710 |
Why?
|
| Body Mass Index | 29 | 2018 | 863 | 0.710 |
Why?
|
| Autoimmune Diseases | 4 | 2018 | 46 | 0.710 |
Why?
|
| American Native Continental Ancestry Group | 4 | 2017 | 11 | 0.700 |
Why?
|
| Gene Expression Regulation | 15 | 2020 | 478 | 0.700 |
Why?
|
| Young Adult | 32 | 2020 | 2648 | 0.690 |
Why?
|
| Quantitative Trait, Heritable | 10 | 2020 | 47 | 0.680 |
Why?
|
| Chromosomes, Human, Pair 1 | 9 | 2016 | 37 | 0.680 |
Why?
|
| Renal Dialysis | 6 | 2017 | 276 | 0.670 |
Why?
|
| Lipids | 7 | 2019 | 253 | 0.660 |
Why?
|
| Rheumatic Diseases | 2 | 2017 | 8 | 0.660 |
Why?
|
| RNA | 1 | 2021 | 94 | 0.650 |
Why?
|
| Muscles | 2 | 2018 | 69 | 0.650 |
Why?
|
| Insulin | 12 | 2018 | 359 | 0.620 |
Why?
|
| Blood Glucose | 13 | 2018 | 484 | 0.620 |
Why?
|
| Vitamin D | 9 | 2018 | 186 | 0.620 |
Why?
|
| Carotid Artery Diseases | 10 | 2016 | 126 | 0.600 |
Why?
|
| Cholesterol, HDL | 10 | 2020 | 181 | 0.600 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2019 | 36 | 0.580 |
Why?
|
| DNA-Binding Proteins | 8 | 2020 | 149 | 0.570 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 6 | 2018 | 36 | 0.560 |
Why?
|
| United States | 40 | 2019 | 4072 | 0.560 |
Why?
|
| Glomerular Filtration Rate | 13 | 2019 | 302 | 0.560 |
Why?
|
| DNA Methylation | 4 | 2020 | 144 | 0.540 |
Why?
|
| Genetic Markers | 16 | 2019 | 124 | 0.540 |
Why?
|
| Genetic Load | 1 | 2017 | 4 | 0.530 |
Why?
|
| Homeostasis | 16 | 2018 | 130 | 0.520 |
Why?
|
| Diabetic Angiopathies | 8 | 2015 | 150 | 0.520 |
Why?
|
| Genetics, Population | 5 | 2015 | 31 | 0.520 |
Why?
|
| Lipase | 3 | 2019 | 30 | 0.510 |
Why?
|
| Triglycerides | 9 | 2020 | 235 | 0.480 |
Why?
|
| Logistic Models | 17 | 2018 | 743 | 0.480 |
Why?
|
| Prospective Studies | 20 | 2020 | 2316 | 0.480 |
Why?
|
| Odds Ratio | 19 | 2017 | 456 | 0.470 |
Why?
|
| Pedigree | 18 | 2018 | 136 | 0.460 |
Why?
|
| Sequence Analysis, RNA | 3 | 2021 | 28 | 0.460 |
Why?
|
| STAT4 Transcription Factor | 6 | 2020 | 15 | 0.450 |
Why?
|
| Cooperative Behavior | 2 | 2005 | 83 | 0.450 |
Why?
|
| Major Histocompatibility Complex | 6 | 2020 | 17 | 0.440 |
Why?
|
| Family | 15 | 2018 | 112 | 0.440 |
Why?
|
| Alcoholism | 2 | 2005 | 97 | 0.440 |
Why?
|
| Sex Characteristics | 6 | 2020 | 173 | 0.440 |
Why?
|
| JC Virus | 4 | 2019 | 20 | 0.430 |
Why?
|
| Databases, Factual | 3 | 2017 | 368 | 0.420 |
Why?
|
| Amyotrophic Lateral Sclerosis | 4 | 2019 | 61 | 0.410 |
Why?
|
| Asian Continental Ancestry Group | 13 | 2019 | 101 | 0.410 |
Why?
|
| C-Reactive Protein | 7 | 2018 | 227 | 0.400 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 7 | 2017 | 81 | 0.400 |
Why?
|
| Gene Expression Profiling | 7 | 2021 | 314 | 0.400 |
Why?
|
| Molecular Epidemiology | 2 | 2017 | 18 | 0.390 |
Why?
|
| Lod Score | 20 | 2018 | 68 | 0.390 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2017 | 907 | 0.390 |
Why?
|
| Epigenesis, Genetic | 5 | 2020 | 109 | 0.380 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2012 | 11 | 0.380 |
Why?
|
| Age of Onset | 9 | 2017 | 90 | 0.380 |
Why?
|
| Promoter Regions, Genetic | 11 | 2019 | 203 | 0.380 |
Why?
|
| Antibodies, Antinuclear | 5 | 2017 | 17 | 0.370 |
Why?
|
| Genetic Testing | 7 | 2019 | 90 | 0.370 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 2017 | 13 | 0.370 |
Why?
|
| Decision Trees | 1 | 2012 | 30 | 0.360 |
Why?
|
| Vitamin D Deficiency | 5 | 2018 | 87 | 0.360 |
Why?
|
| Body Height | 4 | 2021 | 34 | 0.360 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 2 | 2012 | 2 | 0.360 |
Why?
|
| Smoking | 8 | 2019 | 505 | 0.350 |
Why?
|
| Fatty Acid Desaturases | 3 | 2018 | 51 | 0.350 |
Why?
|
| Alcohol Drinking | 3 | 2019 | 255 | 0.350 |
Why?
|
| Reproducibility of Results | 8 | 2021 | 757 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 6 | 6 | 2016 | 20 | 0.340 |
Why?
|
| Child | 18 | 2019 | 2434 | 0.340 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 116 | 0.340 |
Why?
|
| Autoantibodies | 5 | 2019 | 50 | 0.340 |
Why?
|
| Angiopoietin-1 | 1 | 2010 | 1 | 0.330 |
Why?
|
| Chromosomes, Human, X | 2 | 2012 | 13 | 0.330 |
Why?
|
| Epistasis, Genetic | 7 | 2018 | 43 | 0.330 |
Why?
|
| Sequence Analysis, DNA | 10 | 2017 | 132 | 0.330 |
Why?
|
| Bayes Theorem | 6 | 2020 | 82 | 0.320 |
Why?
|
| Chromosomes, Human, Pair 3 | 6 | 2012 | 28 | 0.320 |
Why?
|
| Inflammation | 5 | 2019 | 506 | 0.320 |
Why?
|
| Indians, North American | 6 | 2016 | 75 | 0.320 |
Why?
|
| Autoimmunity | 3 | 2019 | 31 | 0.320 |
Why?
|
| Base Sequence | 6 | 2020 | 252 | 0.310 |
Why?
|
| Adaptor Proteins, Signal Transducing | 6 | 2018 | 69 | 0.310 |
Why?
|
| Interleukin-6 | 5 | 2019 | 224 | 0.310 |
Why?
|
| Brain Ischemia | 3 | 2019 | 159 | 0.310 |
Why?
|
| Interferon Regulatory Factors | 6 | 2017 | 12 | 0.300 |
Why?
|
| Software | 3 | 2021 | 124 | 0.300 |
Why?
|
| Cholesterol, LDL | 5 | 2020 | 170 | 0.300 |
Why?
|
| Severity of Illness Index | 10 | 2021 | 853 | 0.300 |
Why?
|
| Adipocytes | 3 | 2019 | 69 | 0.300 |
Why?
|
| Coronary Vessels | 7 | 2017 | 174 | 0.290 |
Why?
|
| Recovery of Function | 3 | 2020 | 239 | 0.280 |
Why?
|
| Subcutaneous Fat | 4 | 2017 | 44 | 0.280 |
Why?
|
| Carrier Proteins | 4 | 2018 | 144 | 0.280 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 762 | 0.280 |
Why?
|
| Anticoagulants | 2 | 2020 | 122 | 0.280 |
Why?
|
| Spine | 3 | 2018 | 34 | 0.280 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2016 | 215 | 0.280 |
Why?
|
| Glaucoma, Open-Angle | 2 | 2018 | 22 | 0.280 |
Why?
|
| STAT1 Transcription Factor | 3 | 2018 | 13 | 0.270 |
Why?
|
| src-Family Kinases | 2 | 2020 | 15 | 0.270 |
Why?
|
| Introns | 12 | 2018 | 40 | 0.270 |
Why?
|
| Computational Biology | 5 | 2020 | 99 | 0.270 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 4 | 2016 | 16 | 0.260 |
Why?
|
| Palliative Care | 2 | 2018 | 51 | 0.260 |
Why?
|
| Meta-Analysis as Topic | 5 | 2019 | 47 | 0.260 |
Why?
|
| Family Health | 12 | 2011 | 73 | 0.260 |
Why?
|
| Aortic Diseases | 3 | 2016 | 62 | 0.260 |
Why?
|
| Fatty Liver | 3 | 2013 | 70 | 0.260 |
Why?
|
| Apolipoproteins E | 3 | 2019 | 87 | 0.260 |
Why?
|
| Cystitis, Interstitial | 2 | 2019 | 57 | 0.260 |
Why?
|
| Genetics, Medical | 1 | 2007 | 3 | 0.260 |
Why?
|
| Glomerulonephritis | 3 | 2018 | 19 | 0.260 |
Why?
|
| Multivariate Analysis | 11 | 2018 | 651 | 0.250 |
Why?
|
| Cross-Sectional Studies | 15 | 2018 | 1479 | 0.250 |
Why?
|
| Prognosis | 12 | 2019 | 1534 | 0.250 |
Why?
|
| Proteins | 3 | 2020 | 149 | 0.250 |
Why?
|
| Interferons | 2 | 2020 | 16 | 0.250 |
Why?
|
| Multigene Family | 3 | 2017 | 50 | 0.250 |
Why?
|
| Sex Factors | 9 | 2017 | 655 | 0.250 |
Why?
|
| Fibroblast Growth Factors | 2 | 2017 | 37 | 0.250 |
Why?
|
| Europe | 10 | 2021 | 82 | 0.250 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2016 | 160 | 0.240 |
Why?
|
| Cell Adhesion Molecules | 4 | 2019 | 38 | 0.240 |
Why?
|
| Child, Preschool | 10 | 2019 | 1233 | 0.240 |
Why?
|
| Tumor Virus Infections | 2 | 2018 | 21 | 0.240 |
Why?
|
| Polyomavirus Infections | 2 | 2018 | 20 | 0.240 |
Why?
|
| Databases, Genetic | 4 | 2020 | 39 | 0.240 |
Why?
|
| Coronary Disease | 3 | 2018 | 226 | 0.240 |
Why?
|
| Registries | 5 | 2016 | 294 | 0.240 |
Why?
|
| Transcription Factors | 5 | 2019 | 183 | 0.240 |
Why?
|
| Gene Regulatory Networks | 3 | 2020 | 45 | 0.230 |
Why?
|
| Nephritis | 3 | 2015 | 15 | 0.230 |
Why?
|
| Diabetes Complications | 8 | 2013 | 171 | 0.230 |
Why?
|
| Intracranial Aneurysm | 3 | 2012 | 68 | 0.230 |
Why?
|
| Risk Assessment | 14 | 2019 | 1425 | 0.230 |
Why?
|
| Asthma | 4 | 2015 | 261 | 0.220 |
Why?
|
| Nuclear Family | 4 | 2019 | 12 | 0.220 |
Why?
|
| Intracranial Hemorrhage, Hypertensive | 2 | 2016 | 4 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 11 | 5 | 2018 | 24 | 0.220 |
Why?
|
| Texas | 7 | 2014 | 40 | 0.210 |
Why?
|
| Brain | 5 | 2019 | 965 | 0.210 |
Why?
|
| Multifactorial Inheritance | 3 | 2017 | 24 | 0.210 |
Why?
|
| Postural Balance | 2 | 2016 | 142 | 0.210 |
Why?
|
| Pesticides | 2 | 2016 | 135 | 0.210 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2011 | 64 | 0.210 |
Why?
|
| Tissue Donors | 2 | 2016 | 186 | 0.210 |
Why?
|
| Prevalence | 10 | 2017 | 955 | 0.210 |
Why?
|
| Occupational Exposure | 2 | 2016 | 159 | 0.210 |
Why?
|
| Graft Survival | 2 | 2016 | 293 | 0.210 |
Why?
|
| Hypertension, Renal | 2 | 2015 | 27 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 16 | 3 | 2017 | 14 | 0.210 |
Why?
|
| Transients and Migrants | 2 | 2016 | 197 | 0.210 |
Why?
|
| Urine | 3 | 2019 | 69 | 0.210 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2004 | 42 | 0.200 |
Why?
|
| Organ Size | 4 | 2017 | 221 | 0.200 |
Why?
|
| Risk | 8 | 2017 | 305 | 0.200 |
Why?
|
| Anthropometry | 1 | 2003 | 89 | 0.200 |
Why?
|
| Treatment Outcome | 11 | 2020 | 3416 | 0.200 |
Why?
|
| Longitudinal Studies | 7 | 2021 | 757 | 0.200 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2015 | 13 | 0.200 |
Why?
|
| Emigrants and Immigrants | 2 | 2016 | 198 | 0.200 |
Why?
|
| Blood Pressure Determination | 3 | 2020 | 106 | 0.200 |
Why?
|
| Estrogen Receptor alpha | 3 | 2008 | 50 | 0.200 |
Why?
|
| Arteriosclerosis | 6 | 2005 | 147 | 0.200 |
Why?
|
| AIDS-Associated Nephropathy | 2 | 2015 | 10 | 0.200 |
Why?
|
| Principal Component Analysis | 8 | 2016 | 67 | 0.190 |
Why?
|
| Genome | 5 | 2014 | 38 | 0.190 |
Why?
|
| Muscle, Skeletal | 2 | 2019 | 520 | 0.190 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2014 | 12 | 0.190 |
Why?
|
| Kidney Transplantation | 3 | 2016 | 490 | 0.190 |
Why?
|
| Body Fat Distribution | 2 | 2016 | 25 | 0.190 |
Why?
|
| Cognition | 3 | 2016 | 547 | 0.190 |
Why?
|
| Colorado | 6 | 2014 | 43 | 0.190 |
Why?
|
| Gene Expression | 5 | 2020 | 345 | 0.190 |
Why?
|
| Algorithms | 5 | 2016 | 536 | 0.190 |
Why?
|
| Body Composition | 4 | 2005 | 327 | 0.180 |
Why?
|
| Protein Tyrosine Phosphatases | 4 | 2006 | 17 | 0.180 |
Why?
|
| Cell Cycle Proteins | 2 | 2017 | 52 | 0.180 |
Why?
|
| KCNQ1 Potassium Channel | 2 | 2014 | 8 | 0.180 |
Why?
|
| Lipid Metabolism | 3 | 2019 | 108 | 0.180 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 3 | 2017 | 8 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2013 | 267 | 0.180 |
Why?
|
| Urinary Tract Infections | 2 | 2019 | 42 | 0.180 |
Why?
|
| Age Factors | 8 | 2017 | 1179 | 0.180 |
Why?
|
| Follow-Up Studies | 9 | 2018 | 2240 | 0.170 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2017 | 100 | 0.170 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2021 | 18 | 0.170 |
Why?
|
| Pericardium | 3 | 2010 | 52 | 0.170 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2021 | 5 | 0.170 |
Why?
|
| Glucose Tolerance Test | 6 | 2016 | 126 | 0.170 |
Why?
|
| Quality Control | 1 | 2021 | 43 | 0.170 |
Why?
|
| Animals | 15 | 2019 | 8199 | 0.170 |
Why?
|
| Apolipoprotein E2 | 2 | 2018 | 3 | 0.170 |
Why?
|
| Creatinine | 7 | 2019 | 191 | 0.160 |
Why?
|
| Repressor Proteins | 2 | 2017 | 50 | 0.160 |
Why?
|
| INDEL Mutation | 2 | 2018 | 11 | 0.160 |
Why?
|
| Complement C4 | 1 | 2020 | 4 | 0.160 |
Why?
|
| Complement C3 | 1 | 2020 | 11 | 0.160 |
Why?
|
| Insulin-Secreting Cells | 2 | 2018 | 49 | 0.160 |
Why?
|
| HLA-C Antigens | 2 | 2017 | 3 | 0.160 |
Why?
|
| Fasting | 3 | 2016 | 88 | 0.160 |
Why?
|
| Apolipoprotein E4 | 1 | 2020 | 56 | 0.160 |
Why?
|
| Microsatellite Repeats | 4 | 2014 | 22 | 0.160 |
Why?
|
| Ultrasonography | 4 | 2019 | 393 | 0.160 |
Why?
|
| Sjogren's Syndrome | 1 | 2020 | 37 | 0.160 |
Why?
|
| Carotid Arteries | 3 | 2015 | 109 | 0.160 |
Why?
|
| Mutation, Missense | 4 | 2014 | 47 | 0.160 |
Why?
|
| Reference Values | 6 | 2019 | 238 | 0.160 |
Why?
|
| Heart | 4 | 2009 | 177 | 0.150 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2019 | 14 | 0.150 |
Why?
|
| OX40 Ligand | 3 | 2016 | 6 | 0.150 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2016 | 13 | 0.150 |
Why?
|
| Sequence Deletion | 2 | 2017 | 38 | 0.150 |
Why?
|
| PPAR gamma | 2 | 2011 | 51 | 0.150 |
Why?
|
| Antihypertensive Agents | 2 | 2020 | 363 | 0.150 |
Why?
|
| TCF Transcription Factors | 3 | 2008 | 8 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2021 | 1223 | 0.150 |
Why?
|
| Aspartate Aminotransferases | 1 | 2019 | 29 | 0.150 |
Why?
|
| Alanine Transaminase | 1 | 2019 | 47 | 0.150 |
Why?
|
| Proportional Hazards Models | 6 | 2017 | 773 | 0.150 |
Why?
|
| Antigens, Nuclear | 1 | 2019 | 6 | 0.150 |
Why?
|
| Enoyl-CoA Hydratase | 1 | 2019 | 4 | 0.150 |
Why?
|
| Sphingosine | 1 | 2019 | 14 | 0.150 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2019 | 4 | 0.150 |
Why?
|
| Diseases in Twins | 1 | 2019 | 9 | 0.150 |
Why?
|
| Kidney Function Tests | 5 | 2019 | 101 | 0.150 |
Why?
|
| Scleroderma, Systemic | 1 | 2019 | 8 | 0.150 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2019 | 16 | 0.150 |
Why?
|
| Twins, Monozygotic | 1 | 2019 | 13 | 0.150 |
Why?
|
| Hematoma | 1 | 2019 | 26 | 0.150 |
Why?
|
| North Carolina | 10 | 2016 | 1300 | 0.150 |
Why?
|
| Constipation | 1 | 2019 | 12 | 0.150 |
Why?
|
| Lysophospholipids | 1 | 2019 | 26 | 0.150 |
Why?
|
| Myositis, Inclusion Body | 1 | 2019 | 7 | 0.150 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 2 | 2017 | 4 | 0.150 |
Why?
|
| DNA Repair | 1 | 2019 | 55 | 0.150 |
Why?
|
| Chi-Square Distribution | 6 | 2017 | 287 | 0.150 |
Why?
|
| Mutation | 3 | 2017 | 497 | 0.150 |
Why?
|
| Physical Therapy Modalities | 1 | 2019 | 82 | 0.140 |
Why?
|
| Anesthesia | 1 | 2019 | 63 | 0.140 |
Why?
|
| Tracheostomy | 1 | 2019 | 28 | 0.140 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2018 | 12 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2018 | 13 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 4 | 2019 | 124 | 0.140 |
Why?
|
| Transferrin | 1 | 2018 | 26 | 0.140 |
Why?
|
| Intracranial Embolism | 1 | 2018 | 15 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 20 | 2 | 2010 | 7 | 0.140 |
Why?
|
| Colon | 1 | 2019 | 72 | 0.140 |
Why?
|
| Radiodermatitis | 1 | 2018 | 6 | 0.140 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 98 | 0.140 |
Why?
|
| Radiation Injuries | 1 | 2019 | 85 | 0.140 |
Why?
|
| Mice | 8 | 2017 | 2571 | 0.140 |
Why?
|
| Rheumatoid Factor | 1 | 2018 | 4 | 0.140 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2017 | 49 | 0.140 |
Why?
|
| Peripheral Nerves | 1 | 2019 | 60 | 0.140 |
Why?
|
| beta Karyopherins | 2 | 2016 | 6 | 0.140 |
Why?
|
| Cosmic Radiation | 1 | 2018 | 10 | 0.140 |
Why?
|
| Nuclear Proteins | 3 | 2017 | 74 | 0.140 |
Why?
|
| Dipeptidases | 2 | 2009 | 5 | 0.140 |
Why?
|
| Hematopoiesis | 1 | 2018 | 29 | 0.140 |
Why?
|
| Islets of Langerhans | 2 | 2016 | 73 | 0.140 |
Why?
|
| Neoplasm Proteins | 3 | 2013 | 146 | 0.140 |
Why?
|
| Healthcare Disparities | 2 | 2017 | 180 | 0.140 |
Why?
|
| Tunica Intima | 4 | 2013 | 76 | 0.140 |
Why?
|
| Long QT Syndrome | 2 | 2009 | 44 | 0.140 |
Why?
|
| Metabolome | 1 | 2018 | 37 | 0.140 |
Why?
|
| Saliva | 1 | 2018 | 39 | 0.140 |
Why?
|
| Selection, Genetic | 2 | 2015 | 7 | 0.140 |
Why?
|
| Retrospective Studies | 8 | 2019 | 3624 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 167 | 0.140 |
Why?
|
| Leukocytes | 1 | 2018 | 60 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 58 | 0.140 |
Why?
|
| ROC Curve | 6 | 2018 | 169 | 0.140 |
Why?
|
| Nursing Staff, Hospital | 1 | 2017 | 14 | 0.130 |
Why?
|
| Medical Staff, Hospital | 1 | 2017 | 19 | 0.130 |
Why?
|
| Demography | 5 | 2017 | 101 | 0.130 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2017 | 18 | 0.130 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2017 | 24 | 0.130 |
Why?
|
| Heart Block | 1 | 2017 | 10 | 0.130 |
Why?
|
| Calpain | 1 | 2017 | 14 | 0.130 |
Why?
|
| Urinary Bladder | 2 | 2019 | 320 | 0.130 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 114 | 0.130 |
Why?
|
| Hospitalization | 1 | 2020 | 475 | 0.130 |
Why?
|
| Peroxidase | 1 | 2017 | 27 | 0.130 |
Why?
|
| Methylamines | 1 | 2017 | 2 | 0.130 |
Why?
|
| Oxygenases | 1 | 2017 | 3 | 0.130 |
Why?
|
| Cause of Death | 2 | 2015 | 236 | 0.130 |
Why?
|
| Mutagenesis, Insertional | 1 | 2017 | 17 | 0.130 |
Why?
|
| Ultrafiltration | 1 | 2017 | 10 | 0.130 |
Why?
|
| Platelet Transfusion | 1 | 2017 | 15 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 40 | 0.130 |
Why?
|
| Health Status Disparities | 2 | 2016 | 128 | 0.130 |
Why?
|
| Environmental Exposure | 1 | 2017 | 60 | 0.130 |
Why?
|
| Tamoxifen | 1 | 2017 | 59 | 0.130 |
Why?
|
| Zinc Fingers | 1 | 2017 | 9 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2008 | 12 | 0.130 |
Why?
|
| Regression Analysis | 3 | 2006 | 273 | 0.130 |
Why?
|
| Models, Statistical | 4 | 2012 | 187 | 0.130 |
Why?
|
| Intra-Abdominal Fat | 7 | 2013 | 58 | 0.130 |
Why?
|
| Pelvic Pain | 1 | 2017 | 19 | 0.130 |
Why?
|
| Pain | 1 | 2019 | 303 | 0.130 |
Why?
|
| Hypotension | 1 | 2017 | 43 | 0.130 |
Why?
|
| Mitochondrial Diseases | 1 | 2016 | 11 | 0.130 |
Why?
|
| Excitatory Amino Acid Transporter 1 | 1 | 2016 | 3 | 0.130 |
Why?
|
| Neurosurgical Procedures | 1 | 2017 | 94 | 0.130 |
Why?
|
| Receptor, EphB2 | 1 | 2016 | 3 | 0.120 |
Why?
|
| Time Factors | 7 | 2017 | 2204 | 0.120 |
Why?
|
| Laminin | 1 | 2016 | 13 | 0.120 |
Why?
|
| NFI Transcription Factors | 1 | 2016 | 13 | 0.120 |
Why?
|
| Statistics, Nonparametric | 4 | 2017 | 128 | 0.120 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2016 | 7 | 0.120 |
Why?
|
| Pulmonary Fibrosis | 1 | 2016 | 12 | 0.120 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2018 | 165 | 0.120 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 11 | 0.120 |
Why?
|
| Spinal Fractures | 1 | 2016 | 37 | 0.120 |
Why?
|
| Rheumatology | 1 | 2016 | 10 | 0.120 |
Why?
|
| Cerebral Ventricles | 1 | 2016 | 13 | 0.120 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 1 | 2016 | 7 | 0.120 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2016 | 15 | 0.120 |
Why?
|
| Judgment | 1 | 2015 | 12 | 0.120 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2013 | 4 | 0.120 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2015 | 7 | 0.120 |
Why?
|
| Parathyroid Hormone | 1 | 2016 | 46 | 0.120 |
Why?
|
| Open Reading Frames | 2 | 2014 | 21 | 0.120 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2015 | 4 | 0.120 |
Why?
|
| Dementia | 2 | 2017 | 246 | 0.120 |
Why?
|
| Likelihood Functions | 5 | 2017 | 50 | 0.120 |
Why?
|
| DNA, Mitochondrial | 1 | 2015 | 32 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 55 | 0.120 |
Why?
|
| Exercise | 2 | 2019 | 603 | 0.110 |
Why?
|
| Leptin | 1 | 2015 | 61 | 0.110 |
Why?
|
| Receptors, Interleukin | 2 | 2013 | 16 | 0.110 |
Why?
|
| Anticonvulsants | 1 | 2015 | 59 | 0.110 |
Why?
|
| Respiratory System | 1 | 2015 | 11 | 0.110 |
Why?
|
| Urinary Incontinence | 1 | 2016 | 68 | 0.110 |
Why?
|
| Anemia, Sickle Cell | 1 | 2015 | 42 | 0.110 |
Why?
|
| Complement Factor H | 2 | 2014 | 5 | 0.110 |
Why?
|
| Adaptation, Physiological | 1 | 2015 | 53 | 0.110 |
Why?
|
| Caveolin 1 | 1 | 2015 | 13 | 0.110 |
Why?
|
| Collagen Type IV | 1 | 2015 | 10 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 219 | 0.110 |
Why?
|
| Interleukins | 2 | 2013 | 17 | 0.110 |
Why?
|
| Immunity, Innate | 2 | 2012 | 82 | 0.110 |
Why?
|
| DNA Primers | 5 | 2009 | 84 | 0.110 |
Why?
|
| Stress, Physiological | 1 | 2015 | 56 | 0.110 |
Why?
|
| Spectrin | 1 | 2014 | 5 | 0.110 |
Why?
|
| Trachea | 1 | 2015 | 53 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 189 | 0.110 |
Why?
|
| Hippocampus | 1 | 2016 | 216 | 0.110 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2014 | 4 | 0.110 |
Why?
|
| Receptors, Complement 3d | 1 | 2014 | 11 | 0.110 |
Why?
|
| HLA-B27 Antigen | 1 | 2014 | 7 | 0.110 |
Why?
|
| Protein Binding | 4 | 2019 | 244 | 0.110 |
Why?
|
| HMGA2 Protein | 1 | 2014 | 10 | 0.110 |
Why?
|
| Arachidonic Acid | 2 | 2011 | 40 | 0.110 |
Why?
|
| Interleukin-2 | 2 | 2011 | 38 | 0.110 |
Why?
|
| Muscle Proteins | 2 | 2019 | 63 | 0.110 |
Why?
|
| Kidney | 3 | 2013 | 521 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2016 | 461 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2014 | 15 | 0.110 |
Why?
|
| Metabolic Clearance Rate | 1 | 2014 | 18 | 0.110 |
Why?
|
| Muscle, Smooth | 1 | 2015 | 152 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2016 | 178 | 0.100 |
Why?
|
| Molecular Sequence Data | 5 | 2016 | 359 | 0.100 |
Why?
|
| Monocytes | 1 | 2015 | 141 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 410 | 0.100 |
Why?
|
| Selenoprotein P | 1 | 2013 | 2 | 0.100 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2013 | 4 | 0.100 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2013 | 24 | 0.100 |
Why?
|
| Genetic Heterogeneity | 2 | 2004 | 13 | 0.100 |
Why?
|
| Antibodies, Anticardiolipin | 2 | 2013 | 5 | 0.100 |
Why?
|
| Autoantigens | 1 | 2013 | 15 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2013 | 5 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2013 | 31 | 0.100 |
Why?
|
| Diabetes Mellitus | 4 | 2019 | 390 | 0.100 |
Why?
|
| Receptors, IgG | 2 | 2004 | 7 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 140 | 0.100 |
Why?
|
| Glucuronosyltransferase | 1 | 2013 | 5 | 0.100 |
Why?
|
| Interleukin-1 | 2 | 2003 | 48 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 423 | 0.100 |
Why?
|
| Infant, Newborn | 5 | 2017 | 666 | 0.100 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2013 | 10 | 0.100 |
Why?
|
| Haptoglobins | 1 | 2013 | 5 | 0.100 |
Why?
|
| Bilirubin | 1 | 2013 | 23 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2010 | 15 | 0.100 |
Why?
|
| Tomography, Spiral Computed | 1 | 2013 | 19 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 5 | 2014 | 186 | 0.100 |
Why?
|
| Selenoproteins | 1 | 2012 | 3 | 0.100 |
Why?
|
| Indians, South American | 1 | 2012 | 2 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 150 | 0.100 |
Why?
|
| Exons | 5 | 2014 | 52 | 0.090 |
Why?
|
| Actinin | 1 | 2012 | 4 | 0.090 |
Why?
|
| SOXF Transcription Factors | 1 | 2012 | 3 | 0.090 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2012 | 2 | 0.090 |
Why?
|
| Comorbidity | 5 | 2017 | 565 | 0.090 |
Why?
|
| Life Style | 4 | 2019 | 393 | 0.090 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2012 | 7 | 0.090 |
Why?
|
| Chemokine CCL2 | 1 | 2012 | 48 | 0.090 |
Why?
|
| Egg Proteins | 1 | 2012 | 2 | 0.090 |
Why?
|
| Ikaros Transcription Factor | 1 | 2012 | 2 | 0.090 |
Why?
|
| HLA-DR2 Antigen | 2 | 2014 | 3 | 0.090 |
Why?
|
| HLA-DR3 Antigen | 2 | 2014 | 3 | 0.090 |
Why?
|
| Calcium | 3 | 2010 | 339 | 0.090 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2012 | 4 | 0.090 |
Why?
|
| Linear Models | 4 | 2019 | 425 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 4 | 2017 | 792 | 0.090 |
Why?
|
| Heart Ventricles | 1 | 2013 | 146 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2012 | 68 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2011 | 19 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2014 | 349 | 0.090 |
Why?
|
| RNA, Messenger | 4 | 2016 | 499 | 0.090 |
Why?
|
| Protein Phosphatase 2 | 1 | 2011 | 5 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2011 | 1083 | 0.090 |
Why?
|
| Myocardium | 1 | 2012 | 184 | 0.090 |
Why?
|
| Hemoglobin, Sickle | 1 | 2011 | 9 | 0.090 |
Why?
|
| Sickle Cell Trait | 1 | 2011 | 13 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2011 | 10 | 0.090 |
Why?
|
| Lipoproteins | 2 | 2009 | 95 | 0.090 |
Why?
|
| Artificial Intelligence | 1 | 2012 | 63 | 0.090 |
Why?
|
| Stearoyl-CoA Desaturase | 1 | 2011 | 15 | 0.090 |
Why?
|
| Aorta, Abdominal | 2 | 2011 | 31 | 0.090 |
Why?
|
| Protein-Serine-Threonine Kinases | 2 | 2010 | 49 | 0.090 |
Why?
|
| Models, Molecular | 1 | 2011 | 204 | 0.090 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2011 | 36 | 0.090 |
Why?
|
| Africa | 3 | 2021 | 26 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 39 | 0.080 |
Why?
|
| Dietary Sucrose | 1 | 2011 | 10 | 0.080 |
Why?
|
| Diet | 3 | 2011 | 383 | 0.080 |
Why?
|
| Siblings | 4 | 2017 | 23 | 0.080 |
Why?
|
| RGS Proteins | 1 | 2011 | 13 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 83 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2010 | 8 | 0.080 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2010 | 16 | 0.080 |
Why?
|
| Apoptosis | 1 | 2012 | 375 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 57 | 0.080 |
Why?
|
| Genes, Dominant | 3 | 2008 | 27 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2013 | 181 | 0.080 |
Why?
|
| Food Preferences | 1 | 2011 | 34 | 0.080 |
Why?
|
| Trypanosoma brucei rhodesiense | 1 | 2010 | 2 | 0.080 |
Why?
|
| Dietary Fats | 1 | 2011 | 99 | 0.080 |
Why?
|
| Interferon Type I | 1 | 2010 | 11 | 0.080 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2010 | 4 | 0.080 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 69 | 0.080 |
Why?
|
| Americas | 2 | 2010 | 6 | 0.080 |
Why?
|
| Glucuronidase | 1 | 2010 | 12 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2011 | 236 | 0.080 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2010 | 22 | 0.080 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2010 | 45 | 0.080 |
Why?
|
| Isoenzymes | 1 | 2010 | 67 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2010 | 16 | 0.080 |
Why?
|
| Complement C1q | 1 | 2010 | 3 | 0.080 |
Why?
|
| Prostatic Neoplasms | 2 | 2005 | 489 | 0.080 |
Why?
|
| Neutrophils | 2 | 2009 | 120 | 0.080 |
Why?
|
| Neoplasms | 1 | 2017 | 754 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2009 | 8 | 0.080 |
Why?
|
| Survival Rate | 3 | 2019 | 893 | 0.080 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2012 | 40 | 0.080 |
Why?
|
| Recurrence | 2 | 2021 | 285 | 0.080 |
Why?
|
| HLA-DQ Antigens | 2 | 2016 | 8 | 0.080 |
Why?
|
| I-kappa B Proteins | 1 | 2009 | 11 | 0.080 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2009 | 15 | 0.080 |
Why?
|
| Interleukin-21 Receptor alpha Subunit | 1 | 2009 | 1 | 0.080 |
Why?
|
| Entropy | 1 | 2009 | 11 | 0.080 |
Why?
|
| Photosensitivity Disorders | 1 | 2009 | 12 | 0.080 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2009 | 13 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2010 | 114 | 0.080 |
Why?
|
| Stroke Volume | 1 | 2013 | 417 | 0.070 |
Why?
|
| Receptors, Somatostatin | 1 | 2009 | 5 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2009 | 57 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2019 | 839 | 0.070 |
Why?
|
| Immediate-Early Proteins | 1 | 2009 | 8 | 0.070 |
Why?
|
| Calcium-Binding Proteins | 2 | 2019 | 48 | 0.070 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2009 | 3 | 0.070 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 3 | 0.070 |
Why?
|
| Sodium Channels | 1 | 2009 | 16 | 0.070 |
Why?
|
| Cystic Fibrosis | 1 | 2009 | 25 | 0.070 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2020 | 19 | 0.070 |
Why?
|
| Anemia, Hemolytic | 1 | 2008 | 8 | 0.070 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2008 | 10 | 0.070 |
Why?
|
| Tunica Media | 2 | 2013 | 39 | 0.070 |
Why?
|
| Ephrin-B2 | 1 | 2008 | 2 | 0.070 |
Why?
|
| Organ Specificity | 2 | 2019 | 80 | 0.070 |
Why?
|
| Epoxide Hydrolases | 1 | 2008 | 4 | 0.070 |
Why?
|
| CpG Islands | 2 | 2019 | 44 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 51 | 0.070 |
Why?
|
| Radiotherapy | 2 | 2019 | 92 | 0.070 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2008 | 6 | 0.070 |
Why?
|
| Intraocular Pressure | 2 | 2018 | 41 | 0.070 |
Why?
|
| Calcitriol | 1 | 2008 | 29 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2019 | 727 | 0.070 |
Why?
|
| Pyrophosphatases | 1 | 2008 | 2 | 0.070 |
Why?
|
| Absorptiometry, Photon | 2 | 2005 | 98 | 0.070 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2008 | 18 | 0.070 |
Why?
|
| Iron | 2 | 2018 | 94 | 0.070 |
Why?
|
| Proprotein Convertase 2 | 1 | 2007 | 2 | 0.070 |
Why?
|
| Coenzyme A Ligases | 1 | 2007 | 3 | 0.070 |
Why?
|
| Asian Americans | 3 | 2013 | 92 | 0.070 |
Why?
|
| Receptors, Fc | 1 | 2007 | 6 | 0.060 |
Why?
|
| Adult Children | 2 | 2003 | 4 | 0.060 |
Why?
|
| Immunoglobulin A | 1 | 2007 | 12 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 556 | 0.060 |
Why?
|
| Trinucleotide Repeats | 1 | 2007 | 9 | 0.060 |
Why?
|
| Leucine | 1 | 2007 | 23 | 0.060 |
Why?
|
| Cholesterol | 3 | 2019 | 262 | 0.060 |
Why?
|
| Carotid Artery, Common | 2 | 2004 | 48 | 0.060 |
Why?
|
| DNA, Intergenic | 2 | 2020 | 10 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2006 | 19 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2007 | 97 | 0.060 |
Why?
|
| B-Lymphocytes | 2 | 2020 | 79 | 0.060 |
Why?
|
| Lymphotoxin-alpha | 1 | 2006 | 4 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2019 | 299 | 0.060 |
Why?
|
| CD40 Ligand | 1 | 2006 | 12 | 0.060 |
Why?
|
| Argentina | 2 | 2016 | 5 | 0.060 |
Why?
|
| Peru | 2 | 2016 | 21 | 0.060 |
Why?
|
| Pollen | 1 | 2006 | 2 | 0.060 |
Why?
|
| Hypersensitivity | 1 | 2006 | 23 | 0.060 |
Why?
|
| Pro-Opiomelanocortin | 1 | 2005 | 1 | 0.060 |
Why?
|
| P-Selectin | 1 | 2005 | 10 | 0.060 |
Why?
|
| Parkinson Disease | 1 | 2006 | 87 | 0.060 |
Why?
|
| Receptors, Opioid, mu | 1 | 2005 | 36 | 0.060 |
Why?
|
| Body Weight | 2 | 2003 | 323 | 0.060 |
Why?
|
| Genome Components | 1 | 2005 | 2 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 41 | 0.060 |
Why?
|
| Ohio | 2 | 2017 | 63 | 0.060 |
Why?
|
| Carcinoma | 1 | 2005 | 92 | 0.060 |
Why?
|
| Leukoaraiosis | 1 | 2004 | 5 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2005 | 54 | 0.060 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2004 | 12 | 0.050 |
Why?
|
| Diabetic Foot | 1 | 2004 | 23 | 0.050 |
Why?
|
| Statistical Distributions | 1 | 2004 | 5 | 0.050 |
Why?
|
| Preventive Health Services | 1 | 2004 | 39 | 0.050 |
Why?
|
| Electrocardiography | 4 | 2013 | 623 | 0.050 |
Why?
|
| Renal Artery | 1 | 2004 | 47 | 0.050 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 2 | 2016 | 5 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2017 | 454 | 0.050 |
Why?
|
| Sample Size | 1 | 2004 | 38 | 0.050 |
Why?
|
| Penetrance | 1 | 2003 | 4 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2003 | 7 | 0.050 |
Why?
|
| Radioimmunoassay | 1 | 2004 | 25 | 0.050 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2004 | 25 | 0.050 |
Why?
|
| Patient Selection | 2 | 2019 | 272 | 0.050 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2003 | 7 | 0.050 |
Why?
|
| 3' Untranslated Regions | 3 | 2013 | 25 | 0.050 |
Why?
|
| Thrombocytopenia | 2 | 2017 | 30 | 0.050 |
Why?
|
| Immunoglobulin E | 1 | 2003 | 36 | 0.050 |
Why?
|
| Thoracic Vertebrae | 1 | 2004 | 39 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 290 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2004 | 63 | 0.050 |
Why?
|
| Abdomen | 1 | 2003 | 44 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2009 | 471 | 0.050 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2003 | 6 | 0.050 |
Why?
|
| Liver | 2 | 2019 | 492 | 0.050 |
Why?
|
| Waist Circumference | 2 | 2016 | 91 | 0.050 |
Why?
|
| NF-kappa B | 2 | 2013 | 84 | 0.050 |
Why?
|
| Biopsy | 2 | 2016 | 252 | 0.050 |
Why?
|
| Apolipoproteins B | 1 | 2003 | 48 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 158 | 0.050 |
Why?
|
| HLA-DR Antigens | 1 | 2002 | 7 | 0.050 |
Why?
|
| Internet | 1 | 2004 | 202 | 0.050 |
Why?
|
| Systole | 2 | 2018 | 94 | 0.050 |
Why?
|
| Germ-Line Mutation | 2 | 2017 | 15 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2003 | 61 | 0.050 |
Why?
|
| Bone Morphogenetic Protein 4 | 2 | 2013 | 13 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 883 | 0.040 |
Why?
|
| RNA-Binding Proteins | 2 | 2015 | 67 | 0.040 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 2 | 2011 | 14 | 0.040 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2021 | 3 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 3 | 2006 | 19 | 0.040 |
Why?
|
| Lumbar Vertebrae | 2 | 2016 | 97 | 0.040 |
Why?
|
| Isoquinolines | 1 | 2020 | 8 | 0.040 |
Why?
|
| Protein Array Analysis | 1 | 2020 | 14 | 0.040 |
Why?
|
| Heterocyclic Compounds | 1 | 2020 | 14 | 0.040 |
Why?
|
| Trypanosomiasis, African | 2 | 2010 | 6 | 0.040 |
Why?
|
| tRNA Methyltransferases | 2 | 2012 | 5 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 5 | 2 | 2012 | 5 | 0.040 |
Why?
|
| Age Distribution | 3 | 2007 | 194 | 0.040 |
Why?
|
| Body Weights and Measures | 2 | 2011 | 23 | 0.040 |
Why?
|
| Probability | 2 | 2011 | 155 | 0.040 |
Why?
|
| Infant | 2 | 2017 | 1010 | 0.040 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2019 | 9 | 0.040 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2019 | 11 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2019 | 6 | 0.040 |
Why?
|
| Inheritance Patterns | 1 | 2019 | 11 | 0.040 |
Why?
|
| BK Virus | 1 | 2019 | 5 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2011 | 90 | 0.040 |
Why?
|
| Water | 1 | 2019 | 65 | 0.040 |
Why?
|
| Brazil | 1 | 2019 | 15 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2019 | 43 | 0.040 |
Why?
|
| Environment | 1 | 2019 | 47 | 0.040 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2018 | 2 | 0.040 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2018 | 4 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2019 | 32 | 0.040 |
Why?
|
| Forearm | 1 | 2019 | 44 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 96 | 0.040 |
Why?
|
| Virus Replication | 1 | 2019 | 42 | 0.040 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2018 | 1 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2019 | 131 | 0.040 |
Why?
|
| Ferritins | 1 | 2018 | 38 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 73 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 79 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 324 | 0.040 |
Why?
|
| Solar Energy | 1 | 2018 | 3 | 0.040 |
Why?
|
| Bystander Effect | 1 | 2018 | 5 | 0.040 |
Why?
|
| Aging | 1 | 2004 | 942 | 0.030 |
Why?
|
| Protons | 1 | 2018 | 22 | 0.030 |
Why?
|
| Binding Sites | 1 | 2018 | 144 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 112 | 0.030 |
Why?
|
| Homozygote | 2 | 2010 | 52 | 0.030 |
Why?
|
| Body Constitution | 1 | 2018 | 21 | 0.030 |
Why?
|
| Visual Fields | 1 | 2018 | 29 | 0.030 |
Why?
|
| Models, Biological | 2 | 2011 | 408 | 0.030 |
Why?
|
| Receptor, Parathyroid Hormone, Type 1 | 1 | 2017 | 3 | 0.030 |
Why?
|
| Janus Kinase 1 | 1 | 2017 | 5 | 0.030 |
Why?
|
| High Mobility Group Proteins | 1 | 2017 | 7 | 0.030 |
Why?
|
| DNA Damage | 1 | 2018 | 90 | 0.030 |
Why?
|
| Diastole | 1 | 2018 | 98 | 0.030 |
Why?
|
| Fathers | 1 | 2017 | 12 | 0.030 |
Why?
|
| Gene Deletion | 2 | 2011 | 66 | 0.030 |
Why?
|
| Metabolomics | 1 | 2018 | 63 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 454 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 15 | 0.030 |
Why?
|
| Kentucky | 1 | 2017 | 15 | 0.030 |
Why?
|
| Ventriculostomy | 1 | 2017 | 10 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2018 | 76 | 0.030 |
Why?
|
| Seasons | 2 | 2009 | 73 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2017 | 29 | 0.030 |
Why?
|
| Resuscitation Orders | 1 | 2017 | 13 | 0.030 |
Why?
|
| Alcohol-Related Disorders | 1 | 2017 | 21 | 0.030 |
Why?
|
| Telomere | 1 | 2017 | 11 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 78 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 312 | 0.030 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2017 | 1 | 0.030 |
Why?
|
| Procollagen N-Endopeptidase | 1 | 2017 | 1 | 0.030 |
Why?
|
| Interleukin-11 Receptor alpha Subunit | 1 | 2017 | 1 | 0.030 |
Why?
|
| Compliance | 1 | 2017 | 14 | 0.030 |
Why?
|
| Somatomedins | 1 | 2017 | 5 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2017 | 6 | 0.030 |
Why?
|
| Radiography | 2 | 2010 | 362 | 0.030 |
Why?
|
| Proteinuria | 2 | 2010 | 52 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 89 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 81 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 2017 | 23 | 0.030 |
Why?
|
| Mothers | 1 | 2017 | 74 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2018 | 153 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2018 | 341 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2017 | 72 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 79 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2017 | 34 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2017 | 34 | 0.030 |
Why?
|
| Public Health | 1 | 2017 | 91 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2017 | 109 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 194 | 0.030 |
Why?
|
| Genes, Recessive | 2 | 2008 | 8 | 0.030 |
Why?
|
| Skin | 1 | 2018 | 212 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2016 | 43 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 44 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 122 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2016 | 12 | 0.030 |
Why?
|
| Chile | 1 | 2016 | 7 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2016 | 7 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 47 | 0.030 |
Why?
|
| Colombia | 1 | 2015 | 2 | 0.030 |
Why?
|
| South America | 1 | 2015 | 3 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 321 | 0.030 |
Why?
|
| Phosphates | 1 | 2015 | 26 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2008 | 141 | 0.030 |
Why?
|
| Iliac Artery | 1 | 2015 | 50 | 0.030 |
Why?
|
| Physician's Role | 1 | 2015 | 41 | 0.030 |
Why?
|
| Factor XIII | 1 | 2015 | 4 | 0.030 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 5 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2015 | 46 | 0.030 |
Why?
|
| Waist-Hip Ratio | 2 | 2005 | 32 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 19 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 1 | 2016 | 88 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 42 | 0.030 |
Why?
|
| Incidence | 2 | 2011 | 1241 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 477 | 0.030 |
Why?
|
| Databases, Nucleic Acid | 1 | 2014 | 5 | 0.030 |
Why?
|
| Donor Selection | 1 | 2015 | 28 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 246 | 0.030 |
Why?
|
| Receptors, Complement 3b | 1 | 2014 | 7 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2015 | 64 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 250 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 381 | 0.030 |
Why?
|
| North America | 2 | 2004 | 31 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 327 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2014 | 32 | 0.030 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2014 | 18 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 395 | 0.030 |
Why?
|
| Renin-Angiotensin System | 1 | 2015 | 173 | 0.030 |
Why?
|
| Glucose Clamp Technique | 1 | 2014 | 6 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2014 | 19 | 0.030 |
Why?
|
| Angiotensinogen | 1 | 2014 | 59 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 183 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 541 | 0.030 |
Why?
|
| Sp3 Transcription Factor | 1 | 2013 | 1 | 0.030 |
Why?
|
| Lysophospholipase | 1 | 2013 | 5 | 0.030 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2013 | 9 | 0.030 |
Why?
|
| Quality of Life | 1 | 2019 | 964 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2013 | 14 | 0.020 |
Why?
|
| Receptors, Adiponectin | 1 | 2013 | 3 | 0.020 |
Why?
|
| Educational Status | 1 | 2014 | 167 | 0.020 |
Why?
|
| NADH Dehydrogenase | 1 | 2013 | 4 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 95 | 0.020 |
Why?
|
| Receptors, CCR | 1 | 2013 | 1 | 0.020 |
Why?
|
| Muramidase | 1 | 2013 | 8 | 0.020 |
Why?
|
| Glutathione Reductase | 1 | 2013 | 9 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2013 | 18 | 0.020 |
Why?
|
| Cystatin C | 1 | 2013 | 33 | 0.020 |
Why?
|
| Bone Resorption | 1 | 2013 | 11 | 0.020 |
Why?
|
| Disease Susceptibility | 2 | 2003 | 61 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2013 | 55 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 77 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2013 | 55 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2004 | 174 | 0.020 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2013 | 18 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 193 | 0.020 |
Why?
|
| HLA-B Antigens | 1 | 2012 | 1 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 18 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2012 | 23 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 129 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 603 | 0.020 |
Why?
|
| Cheek | 1 | 2012 | 6 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 76 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 444 | 0.020 |
Why?
|
| Morbidity | 1 | 2012 | 98 | 0.020 |
Why?
|
| Heredity | 1 | 2012 | 12 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2012 | 30 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 126 | 0.020 |
Why?
|
| Ribonucleoproteins | 1 | 2012 | 15 | 0.020 |
Why?
|
| ADAM Proteins | 1 | 2012 | 12 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 6 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2011 | 1 | 0.020 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2011 | 5 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2012 | 32 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 50 | 0.020 |
Why?
|
| California | 1 | 2011 | 61 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 2011 | 24 | 0.020 |
Why?
|
| Asia | 1 | 2011 | 19 | 0.020 |
Why?
|
| Crohn Disease | 1 | 2011 | 31 | 0.020 |
Why?
|
| Oral Ulcer | 1 | 2011 | 5 | 0.020 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2011 | 7 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2011 | 20 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2011 | 13 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2011 | 32 | 0.020 |
Why?
|
| Bronchi | 1 | 2011 | 33 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 388 | 0.020 |
Why?
|
| Saint Kitts and Nevis | 1 | 2011 | 4 | 0.020 |
Why?
|
| Autopsy | 1 | 2011 | 37 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 163 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2010 | 20 | 0.020 |
Why?
|
| Phosphorus | 1 | 2010 | 11 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 140 | 0.020 |
Why?
|
| Skin Physiological Phenomena | 1 | 2010 | 7 | 0.020 |
Why?
|
| Endocrine System Diseases | 1 | 2010 | 4 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2011 | 81 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2011 | 60 | 0.020 |
Why?
|
| Japan | 1 | 2010 | 19 | 0.020 |
Why?
|
| Health Behavior | 1 | 2012 | 211 | 0.020 |
Why?
|
| China | 1 | 2010 | 56 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2010 | 7 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2010 | 8 | 0.020 |
Why?
|
| Nephrotic Syndrome | 1 | 2010 | 11 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2010 | 22 | 0.020 |
Why?
|
| Urologic Diseases | 1 | 2010 | 35 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 2010 | 25 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 264 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2010 | 28 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2009 | 21 | 0.020 |
Why?
|
| Particle Size | 1 | 2009 | 48 | 0.020 |
Why?
|
| Aorta | 1 | 2010 | 125 | 0.020 |
Why?
|
| Abdominal Fat | 1 | 2009 | 39 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2009 | 22 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2009 | 40 | 0.020 |
Why?
|
| South Carolina | 1 | 2008 | 29 | 0.020 |
Why?
|
| Receptors, Drug | 1 | 2008 | 19 | 0.020 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2008 | 5 | 0.020 |
Why?
|
| Urban Population | 1 | 2009 | 91 | 0.020 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2008 | 9 | 0.020 |
Why?
|
| Receptors, Calcitriol | 1 | 2008 | 13 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 257 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2008 | 58 | 0.020 |
Why?
|
| Cation Transport Proteins | 1 | 2008 | 22 | 0.020 |
Why?
|
| Los Angeles | 1 | 2008 | 8 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2008 | 43 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 83 | 0.020 |
Why?
|
| Southeastern United States | 1 | 2008 | 75 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 75 | 0.020 |
Why?
|
| Rural Population | 1 | 2009 | 216 | 0.020 |
Why?
|
| Cell Degranulation | 1 | 2007 | 2 | 0.020 |
Why?
|
| Endocytosis | 1 | 2007 | 9 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2007 | 19 | 0.020 |
Why?
|
| Carnosine | 1 | 2007 | 3 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2007 | 94 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2006 | 11 | 0.020 |
Why?
|
| Motor Activity | 1 | 2009 | 332 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2008 | 139 | 0.020 |
Why?
|
| Physical Chromosome Mapping | 1 | 2006 | 8 | 0.020 |
Why?
|
| Estrogens | 1 | 2007 | 194 | 0.020 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2005 | 12 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2005 | 3 | 0.010 |
Why?
|
| Postmenopause | 1 | 2007 | 424 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2005 | 110 | 0.010 |
Why?
|
| Aspartic Acid | 1 | 2005 | 13 | 0.010 |
Why?
|
| Threonine | 1 | 2005 | 11 | 0.010 |
Why?
|
| Viscera | 1 | 2005 | 13 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 34 | 0.010 |
Why?
|
| Tissue Embedding | 1 | 2004 | 2 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 729 | 0.010 |
Why?
|
| Serum | 1 | 2004 | 14 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2004 | 40 | 0.010 |
Why?
|
| Solubility | 1 | 2004 | 39 | 0.010 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2004 | 14 | 0.010 |
Why?
|
| Microcirculation | 1 | 2004 | 66 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 2005 | 50 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2004 | 9 | 0.010 |
Why?
|
| Cadaver | 1 | 2004 | 151 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2004 | 26 | 0.010 |
Why?
|
| Energy Intake | 1 | 2005 | 122 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2005 | 132 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2004 | 32 | 0.010 |
Why?
|
| Coronary Stenosis | 1 | 2004 | 28 | 0.010 |
Why?
|
| Physical Examination | 1 | 2004 | 86 | 0.010 |
Why?
|
| Radiography, Abdominal | 1 | 2004 | 15 | 0.010 |
Why?
|
| Cysteine | 1 | 2005 | 145 | 0.010 |
Why?
|
| Skin Tests | 1 | 2003 | 13 | 0.010 |
Why?
|
| Carotid Stenosis | 1 | 2004 | 59 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2008 | 465 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 143 | 0.010 |
Why?
|
| Electrophoresis | 1 | 2003 | 8 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 232 | 0.010 |
Why?
|
| Founder Effect | 1 | 2002 | 5 | 0.010 |
Why?
|
| Rats | 1 | 2007 | 1895 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2002 | 23 | 0.010 |
Why?
|